Replies to post #195357 on Biotech Values

[DewDiligence]

ICPT reports phase-2 NASH data in Japanese patients—data not as strong as the phase-2 FLINT study:

http://finance.yahoo.com/news/intercept-pharmaceuticals-announces-results-phase-113000409.html

The ITT results in the table below show a dose dependent increase in the percentage of OCA treated patients compared to placebo who achieved the primary endpoint (p=0.053, not significant).

The 40mg OCA dose group achieved statistical significance on the primary endpoint compared to placebo (p=0.0496).